unknown
Stage
About
Azevan Pharmaceuticals is developing vasopressin V1a receptor antagonists as targeted treatments for pathological aggression and neurological injury in CNS disorders and traumatic brain injury.
Explore Azevan's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.